Cresset Asset Management’s Haemonetics HAE Stock Holding History

Cresset Asset Management’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-6	Closed	-$1K	–	962
2019 Q1	$1K	Buy	+6	New	+$546	﹤0.01%	1800

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Cresset Asset Management's HAE Position: Q2 2019 in Review

Cresset Asset Management sold out of Haemonetics (HAE) in Q2 2019, closing a stake of 6 shares — an estimated $1K sold.

Cresset Asset Management first reported a position in HAE in Q1 2019 and held it in 1 quarter. The position peaked at $1K in Q1 2019. 256 funds tracked by Wall St. Rank hold HAE as of Q2 2019.

Cresset Asset Management reported no remaining Haemonetics position as of Q2 2019 after selling out during the quarter.
Cresset Asset Management sold 6 Haemonetics shares in Q2 2019, an estimated $1K.
Cresset Asset Management first reported a position in Haemonetics in Q1 2019 and held it in 1 quarter.
Cresset Asset Management's Haemonetics position peaked at $1K in Q1 2019.
256 funds tracked by Wall St. Rank held Haemonetics as of Q2 2019.

Based on Cresset Asset Management's 13F filing for Q2 2019, filed 12 Aug 2019.